Cell Source, Inc. Deferred Income Tax Expense (Benefit)
Cell Source, Inc. (CLCS) reported Deferred Income Tax Expense (Benefit) of -$1.26 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-04-07
- Cell Source, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$1.26M.
- Cell Source, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$1.48M.
- Cell Source, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$754.66K.
- Cell Source, Inc. deferred income tax expense (benefit) for fiscal 2021 was -$1.77M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | -$1.26M 10-K · filed 2026-04-07 |
| 2023-12-31 | -$1.48M 10-K · filed 2026-04-07 |
| 2022-12-31 | -$754.66K 10-K · filed 2024-06-24 |
| 2021-12-31 | -$1.77M 10-K · filed 2023-08-08 |
| 2020-12-31 | -$1.54M 10-K · filed 2022-04-15 |